Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Copper transporter 1 affinity as a delivery strategy to improve the cytotoxic profile of rationally designed copper(II) complexes for cancer treatment

Full text
Author(s):
Gomes Teles, Ramon Handerson [1] ; Graminha, Angelica Ellen [1] ; Rivera-Cruz, Cosette M. [2] ; Nakahata, Douglas Hideki [3] ; Barboza Formiga, Andre Luiz [3] ; Corbi, Pedro Paulo [3] ; Figueiredo, Marxa Leao [2] ; Cominetti, Marcia Regina [1]
Total Authors: 8
Affiliation:
[1] Univ Fed Sao Carlos, Dept Gerontol, Rod Washington Luis, Km 235, Sao Carlos, SP - Brazil
[2] Purdue Univ, Dept Basic Med Sci, Coll Vet Med, 625 Harrison St, W Lafayette, IN 47907 - USA
[3] Univ Estadual Campinas, Inst Chem, UNICAMP, BR-13083970 Campinas, SP - Brazil
Total Affiliations: 3
Document type: Journal article
Source: TOXICOLOGY IN VITRO; v. 67, SEP 2020.
Web of Science Citations: 0
Abstract

Cisplatin is widely used to treat different types of cancer, but its severe side effects are the major disadvantage of this treatment. Therefore, other metals are currently the subject of research in the rational development of anticancer drugs, such as copper, that has been demonstrated to be promising in this scenario. Here, we evaluated the effects of two novel copper complexes against breast cancer cell lines, and also examined the influence of overexpressing copper transporter 1 (CTR1) on the cytotoxicity of these complexes. Complex (1) {[}Cu (sdmx(-))(2)(phen)] showed low IC50 values, induced intense cell morphological changes and arrested the cell cycle at the sub-G1 phase in cancer cells. Complex (1) was tested in transfected cells overexpressing the CTR1 receptor in order to compare its steric effects with a less bulky ligand and more labile complex (2) {[}CuCl2(impy)]. A significant reduction of IC50 value was observed in CTR1 overexpressing cells for complex (2) (32 mu M to 20 mu M) as compared to (1) (2.78 mu M to 3.41 mu M), evidencing a possible uptake through copper reduction (Cu+2 -> Cu+1) mediated by CTR1. Thus, considering that CTR1 is a mediator of metallodrugs uptake, the development of strategies that use rational drug design is important in order to improve the therapeutic efficacy through greater specificity and consecutive reduction of side effects. Here we show the example for the case of copper(II) complexes. (AU)

FAPESP's process: 18/12062-4 - Synthesis, characterization and studies of interaction with biomolecules of metal complexes containing biologically active ligands: a strategy in the preparation of new agents with antibacterial and antiviral activities
Grantee:Pedro Paulo Corbi
Support type: Regular Research Grants
FAPESP's process: 15/20882-3 - Metal complexes of sulfamethoxydiazine and sulfadimethoxine: synthesis, characterization and applications as antimicrobial agents for topical use
Grantee:Douglas Hideki Nakahata
Support type: Scholarships in Brazil - Doctorate
FAPESP's process: 18/17170-0 - Importance of the copper transporter 1 receptor in the uptake of the copper complex [Cu(sdmx)2(phen)] into triple negative breast tumor cells
Grantee:Ramon Handerson Gomes Teles
Support type: Scholarships abroad - Research Internship - Master's degree
FAPESP's process: 13/07600-3 - CIBFar - Center for Innovation in Biodiversity and Drug Discovery
Grantee:Glaucius Oliva
Support type: Research Grants - Research, Innovation and Dissemination Centers - RIDC
FAPESP's process: 17/19504-0 - Evaluation of the activity of ruthenium complexes encapsulated in triple-negative breast tumor metastases
Grantee:Ramon Handerson Gomes Teles
Support type: Scholarships in Brazil - Master